142 related articles for article (PubMed ID: 37380459)
1. Clinical Response of Primary Malignant Pericardial Mesothelioma with Peritoneal Dissemination to Nivolumab.
Fujiwara S; Kano Y; Maejima Y; Fujioka T; Tamura K; Kirimura S; Miyake S; Okamoto R
Intern Med; 2024 Feb; 63(4):513-519. PubMed ID: 37380459
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report.
Ikushima H; Sakatani T; Ohara S; Takeshima H; Horiuchi H; Morikawa T; Usui K
Medicine (Baltimore); 2020 May; 99(22):e19956. PubMed ID: 32481365
[TBL] [Abstract][Full Text] [Related]
3. Malignant peritoneal mesothelioma.
Chun CP; Song LX; Zhang HP; Guo DD; Xu GX; Li Y; Xin X; Cao J; Li F
Am J Med Sci; 2023 Jan; 365(1):99-103. PubMed ID: 35940275
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
[No Abstract] [Full Text] [Related]
5. A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites.
Komaki T; Urata H; Mori K; Iwashita A; Ikeda K; Haraoka S
Intern Med; 2017; 56(7):861-864. PubMed ID: 28381756
[TBL] [Abstract][Full Text] [Related]
6. [A case of ascities decrease in malignant peritoneal mesothelioma by weekly intra-peritoneal administration of cisplatin and paclitaxel].
Ami K; Nagahama T; Andou M; Nawa K; Ganno H; Ohbu M; Kimu K; Ito T; Yamauchi A; Ichikawa S; Kobo T; Takaba E
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1709-11. PubMed ID: 16315916
[TBL] [Abstract][Full Text] [Related]
7. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
[TBL] [Abstract][Full Text] [Related]
8. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab for malignant peritoneal mesothelioma.
Tanaka T; Miyamoto Y; Sakai A; Fujimoto N
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257382
[TBL] [Abstract][Full Text] [Related]
10. Malignant Peritoneal Mesothelioma Presenting with Polymyalgia Rheumatica-like Syndrome.
Ide Y; Yuki T; Taooka Y; Higashi Y; Tachiyama Y
Intern Med; 2020 Oct; 59(20):2629-2632. PubMed ID: 32581164
[TBL] [Abstract][Full Text] [Related]
11. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
Nakamura A; Kondo N; Nakamichi T; Kuroda A; Hashimoto M; Matsumoto S; Yokoi T; Kuribayashi K; Kijima T; Hasegawa S
Jpn J Clin Oncol; 2020 Aug; 50(8):920-925. PubMed ID: 32463095
[TBL] [Abstract][Full Text] [Related]
12. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
13. Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report.
Tang LK; Li ZK; Xiang YL; Ma DY; Du GB
Medicine (Baltimore); 2023 Jul; 102(30):e34349. PubMed ID: 37505161
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
[TBL] [Abstract][Full Text] [Related]
15. [Malignant Peritoneal Mesothelioma Diagnosed as an Inguinal Mass : A Case Report].
Araki Y; Ikeda M; Iribe Y; Asaoka M; Uemura K; Sano F; Ikeda I
Hinyokika Kiyo; 2021 Oct; 67(10):475-477. PubMed ID: 34742174
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
[TBL] [Abstract][Full Text] [Related]
17. Diffuse malignant peritoneal mesothelioma.
Shih CA; Ho SP; Tsay FW; Lai KH; Hsu PI
Kaohsiung J Med Sci; 2013 Nov; 29(11):642-5. PubMed ID: 24183360
[TBL] [Abstract][Full Text] [Related]
18. High density and proximity of CD8
Yin Y; Sakakibara R; Honda T; Kirimura S; Daroonpan P; Kobayashi M; Ando K; Ujiie H; Kato T; Kaga K; Mitsumura T; Nakano R; Sakashita H; Matsuge S; Ishibashi H; Akashi T; Hida Y; Morohoshi T; Azuma M; Okubo K; Miyazaki Y
Thorac Cancer; 2023 Jul; 14(20):1991-2000. PubMed ID: 37253418
[TBL] [Abstract][Full Text] [Related]
19. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
Desai AP; Kosari F; Disselhorst M; Yin J; Agahi A; Peikert T; Udell J; Johnson SH; Smadbeck J; Murphy S; Karagouga G; McCune A; Schaefer-Klein J; Borad MJ; Cheville J; Vasmatzis G; Baas P; Mansfield A
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37279993
[TBL] [Abstract][Full Text] [Related]
20. Malignant Peritoneal Mesothelioma with Latent Tuberculosis Infection.
Inoue N; Takumi K; Sone D; Shirakawa A; Kawamura T; Uno K
Intern Med; 2021 Nov; 60(21):3409-3412. PubMed ID: 33840700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
